Open AccessSafety Profile of Good Manufacturing Practice Manufactured Interferon γ‐Primed Mesenchymal Stem/Stromal Cells for Clinical Trials
Author(s) -
Guess Adam J.,
Daneault Beth,
Wang Rongzhang,
Bradbury Hillary,
La Perle Krista M. D.,
Fitch James,
Hedrick Sheri L.,
Hamelberg Elizabeth,
Astbury Caroline,
White Peter,
Overolt Kathleen,
Rangarajan Hemalatha,
AbuArja Rolla,
Devine Steven M.,
Otsuru Satoru,
Dominici Massimo,
O'Donnell Lynn,
Horwitz Edwin M.
Publication year - 2017
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.1002/sctm.16-0485
Subject(s) - mesenchymal stem cell , medicine , stem cell , immune system , clinical trial , haematopoiesis , good manufacturing practice , immunology , cytokine , cancer research , cell therapy , biology , pathology , microbiology and biotechnology , regulatory affairs
Mesenchymal stem/stromal cells (MSCs) are widely studied by both academia and industry for a broad array of clinical indications. The collective body of data provides compelling evidence of the clinical safety of MSC therapy. However, generally accepted proof of therapeutic efficacy has not yet been reported. In an effort to generate a more effective therapeutic cell product, investigators are focused on modifying MSC processing protocols to enhance the intrinsic biologic activity. Here, we report a Good Manufacturing Practice‐compliant two‐step MSC manufacturing protocol to generate MSCs or interferon γ (IFNγ) primed MSCs which allows freshly expanded cells to be infused in patients on a predetermined schedule. This protocol eliminates the need to infuse cryopreserved, just thawed cells which may reduce the immune modulatory activity. Moreover, using (IFNγ) as a prototypic cytokine, we demonstrate the feasibility of priming the cells with any biologic agent. We then characterized MSCs and IFNγ primed MSCs prepared with our protocol, by karyotype, in vitro potential for malignant transformation, biodistribution, effect on engraftment of transplanted hematopoietic cells, and in vivo toxicity in immune deficient mice including a complete post‐mortem examination. We found no evidence of toxicity attributable to the MSC or IFNγ primed MSCs. Our data suggest that the clinical risk of infusing MSCs or IFNγ primed MSCs produced by our two‐step protocol is not greater than MSCs currently in practice. While actual proof of safety requires phase I clinical trials, our data support the use of either cell product in new clinical studies. S tem C ells T ranslational M edicine 2017;6:1868–1879